PPAR-gamma Ligand Activation Decreases Aromatase Expression in Endometrial Stromal Cells
S. K. Kavoussi,K. M. J. Menon,H. Peegel,G. M. Christman,S.-W. Guo,D. I. Lebovic
DOI: https://doi.org/10.1016/j.fertnstert.2007.07.211
IF: 6.7
2007-01-01
Fertility and Sterility
Abstract:ObjectiveLocal production of estrogen via upregulated aromatase (CYP19, p450 arom) expression contributes to the persistence and self-propagation of endometriotic lesions. PPAR-γ ligands have been shown to decrease p450 arom in human granulosa cells. We sought to determine if a PPAR-γ ligand, ciglitazone (CIG), could affect aromatase expression in endometrial stromal cells.DesignIn vitro study using the human endometrial stromal cell line YHES.Materials and methodsExpression of PPAR-γ in YHES cells was demonstrated utilizing reverse transcriptase polymerase chain reaction (RT-PCR). YHES cells were plated and grown to confluence in 60 mm dishes × 48 hrs. Cells were then treated with IL-1β and/or CIG × 24 hrs. RNA isolation and extraction was performed. After total RNA was reverse transcribed to cDNA, real-time PCR was performed using the Real-Time 7300 System. Replicates consisted of: a) control (no IL-1β or CIG), b) IL-1β, c) CIG, and d) IL-1β + CIG. After treatment, real time-polymerase chain reaction was performed to quantify aromatase expression. Comparisons of aromatase expression between treatment groups were made using a one-way ANOVA with post hoc Bonferroni test.ResultsWe show the presence of PPAR-γ in YHES cells by RT-PCR. There was no difference in aromatase mRNA expression when the cells were treated with CIG alone. However, IL-1β (0.6 nM) increased aromatase expression by over 6-fold. When the YHES endometrial stromal cells were stimulated with IL-1β and CIG (40 μM), there was a statistically significant decrease in aromatase mRNA expression compared to IL-1β alone (P=0.026).ConclusionsCIG treatment significantly decreased aromatase expression in IL-1β-treated endometrial stromal cell line that harbors PPAR-γ. The downregulation of local aromatase production via PPAR-γ activation may facilitate regression of endometriotic lesions in patients with established disease. Hence, thiazolidinediones such as rosiglitazone may prove to be a useful treatment option for endometriosis-related pain and/or infertility. ObjectiveLocal production of estrogen via upregulated aromatase (CYP19, p450 arom) expression contributes to the persistence and self-propagation of endometriotic lesions. PPAR-γ ligands have been shown to decrease p450 arom in human granulosa cells. We sought to determine if a PPAR-γ ligand, ciglitazone (CIG), could affect aromatase expression in endometrial stromal cells. Local production of estrogen via upregulated aromatase (CYP19, p450 arom) expression contributes to the persistence and self-propagation of endometriotic lesions. PPAR-γ ligands have been shown to decrease p450 arom in human granulosa cells. We sought to determine if a PPAR-γ ligand, ciglitazone (CIG), could affect aromatase expression in endometrial stromal cells. DesignIn vitro study using the human endometrial stromal cell line YHES. In vitro study using the human endometrial stromal cell line YHES. Materials and methodsExpression of PPAR-γ in YHES cells was demonstrated utilizing reverse transcriptase polymerase chain reaction (RT-PCR). YHES cells were plated and grown to confluence in 60 mm dishes × 48 hrs. Cells were then treated with IL-1β and/or CIG × 24 hrs. RNA isolation and extraction was performed. After total RNA was reverse transcribed to cDNA, real-time PCR was performed using the Real-Time 7300 System. Replicates consisted of: a) control (no IL-1β or CIG), b) IL-1β, c) CIG, and d) IL-1β + CIG. After treatment, real time-polymerase chain reaction was performed to quantify aromatase expression. Comparisons of aromatase expression between treatment groups were made using a one-way ANOVA with post hoc Bonferroni test. Expression of PPAR-γ in YHES cells was demonstrated utilizing reverse transcriptase polymerase chain reaction (RT-PCR). YHES cells were plated and grown to confluence in 60 mm dishes × 48 hrs. Cells were then treated with IL-1β and/or CIG × 24 hrs. RNA isolation and extraction was performed. After total RNA was reverse transcribed to cDNA, real-time PCR was performed using the Real-Time 7300 System. Replicates consisted of: a) control (no IL-1β or CIG), b) IL-1β, c) CIG, and d) IL-1β + CIG. After treatment, real time-polymerase chain reaction was performed to quantify aromatase expression. Comparisons of aromatase expression between treatment groups were made using a one-way ANOVA with post hoc Bonferroni test. ResultsWe show the presence of PPAR-γ in YHES cells by RT-PCR. There was no difference in aromatase mRNA expression when the cells were treated with CIG alone. However, IL-1β (0.6 nM) increased aromatase expression by over 6-fold. When the YHES endometrial stromal cells were stimulated with IL-1β and CIG (40 μM), there was a statistically significant decrease in aromatase mRNA expression compared to IL-1β alone (P=0.026). We show the presence of PPAR-γ in YHES cells by RT-PCR. There was no difference in aromatase mRNA expression when the cells were treated with CIG alone. However, IL-1β (0.6 nM) increased aromatase expression by over 6-fold. When the YHES endometrial stromal cells were stimulated with IL-1β and CIG (40 μM), there was a statistically significant decrease in aromatase mRNA expression compared to IL-1β alone (P=0.026). ConclusionsCIG treatment significantly decreased aromatase expression in IL-1β-treated endometrial stromal cell line that harbors PPAR-γ. The downregulation of local aromatase production via PPAR-γ activation may facilitate regression of endometriotic lesions in patients with established disease. Hence, thiazolidinediones such as rosiglitazone may prove to be a useful treatment option for endometriosis-related pain and/or infertility. CIG treatment significantly decreased aromatase expression in IL-1β-treated endometrial stromal cell line that harbors PPAR-γ. The downregulation of local aromatase production via PPAR-γ activation may facilitate regression of endometriotic lesions in patients with established disease. Hence, thiazolidinediones such as rosiglitazone may prove to be a useful treatment option for endometriosis-related pain and/or infertility.